Prelude Therapeutics
PRLD Small CapHealthcare · Biotechnology
Mis à jour: Aug 2, 2026, 22:14 UTC
Price Chart
Indicateurs clés
Valuation Analysis
About the Company
Prelude Therapeutics en bref
Prelude Therapeutics (PRLD) is currently trading at 3,99 € with a market capitalization of 318 M €. The 52-week range spans from 0,65 € to 4,93 €; the current price is 19.2% below the yearly high.
💰 Dividende
Prelude Therapeutics currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.
📊 Avis des analystes
3 analystes évaluent Prelude Therapeutics (PRLD) au consensus : Achat Fort. L'objectif de cours moyen est de 6,94 €, soit un potentiel de +73.91% par rapport au cours actuel. La fourchette des objectifs de cours des analystes va de 5,20 € à 8,67 €.
Prelude Therapeutics : la thèse d'investissement en détail
Prelude Therapeutics (PRLD) operates in the Healthcare — specifically Biotechnology — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.
Le scénario haussier
With a gross margin near 100%, the company sits in the top tier of its industry — these are the kinds of structural margins that protect earnings during downturns. Wall Street consensus sits at Strong Buy with an average price target implying roughly 73.91% upside from current levels — analyst sentiment is firmly constructive.
Le scénario baissier
Short interest sits at 13.06% of float — a meaningful contingent of professionals is positioned for the share to fall, which deserves attention even if their thesis may turn out to be wrong.
À surveiller
- The analyst consensus price target implies 73.91% upside — if the next two quarters confirm the underlying thesis, target hikes typically follow.
Thèse d'investissement : forces et faiblesses
- Marge brute élevée de 100% — signe d'un pouvoir de fixation des prix
- Consensus des analystes : Strong Buy
- Bilan solide avec faible endettement (D/E 29.45)
- –Positions vendeuses élevées (13.06%)
- –Free cash flow négatif
Aperçu technique
Price trades above both the 50- and 200-day moving averages, with 50d above 200d — a classic bullish setup (golden-cross alignment).
Profil de risque
The data points to relatively defensive market behavior, elevated short interest (13.06%).
Trading Data
Related Stocks in the Same Sector
More Santé stocks
Top peers in the same sector — ranked by market cap.
Where can I buy Prelude Therapeutics?
Compare top-rated brokers — low fees, trusted providers, fully regulated.
📊 Plutôt un fonds qu’une action isolée ? Comparatif d’ETF :
Live Market Data
Real-time chart, financials, earnings, analysts, insider trades, events & news
